Beaumont Financial Advisors LLC Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Beaumont Financial Advisors LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the fourth quarter, Holdings Channel reports. The firm owned 2,182 shares of the medical research company’s stock after purchasing an additional 33 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,158,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Thermo Fisher Scientific by 0.6% during the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after buying an additional 180,618 shares during the period. Morgan Stanley increased its stake in shares of Thermo Fisher Scientific by 0.4% during the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after buying an additional 50,736 shares during the period. Moneta Group Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 104,536.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after buying an additional 8,347,260 shares during the period. Providence Capital Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 61,754.7% during the first quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after buying an additional 5,832,730 shares during the period. Finally, Norges Bank acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $3,105,677,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TMO shares. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. The Goldman Sachs Group upped their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Finally, HSBC increased their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $544.79 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The stock has a fifty day moving average price of $571.27 and a 200 day moving average price of $527.45. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a market cap of $207.95 billion, a PE ratio of 35.26, a P/E/G ratio of 2.28 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same period last year, the company earned $5.40 earnings per share. The company’s revenue for the quarter was down 4.9% on a year-over-year basis. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.